InvestorsHub Logo
Followers 57
Posts 11404
Boards Moderated 0
Alias Born 02/09/2009

Re: None

Wednesday, 08/21/2024 9:34:32 AM

Wednesday, August 21, 2024 9:34:32 AM

Post# of 565
This Morning: TNF Pharmaceuticals Prepares to Advance Lead Clinical Program Targeting Age-Related Decline

MYMD-1® development to continue through fully funded mid-stage clinical trials

Clinical study of MYMD-1 in sarcopenia/frailty met primary endpoints for significantly reducing chronic inflammatory markers with statistical significance

MYMD-1 shown to inhibit excessive activity of TNF-alpha to regulate the immuno-metabolic system

Company holds FDA-cleared Phase 2 INDs for MYMD-1 in two additional chronic inflammatory conditions, rheumatoid arthritis and Hashimoto’s thyroiditis

Press Release here: https://www.businesswire.com/news/home/20240821460281/en/

"Prepares to advance" — this statement tells us nothing, and the content of the release adds nothing to what is already known.

The new president, Dr. Glass, is quoted as saying, "Our next steps, to be revealed soon, will extend our reach toward significant and sustainable value creation, and long-term Company growth.” <-- If this "to be revealed soon" news is substantial it will prove that today's release was not just an attempt to boost the stock price.

As has been said by critical_perspective we have good reason for skepticism. Today's pre-market action shows that there are some who are taking this release as an opportunity to get out. I hope they will be proven to have misjudged the new management. The science is real and good. What's needed is action. We may be past the point where promises of action will inspire anything.